Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

August 30th 2015

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

New FIRE-3 Analysis Shows Importance of Subsequent Therapies on mCRC Outcomes

August 28th 2015

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

Coffee May Reduce Colon Cancer Recurrence by Over 40%

August 21st 2015

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Shifting the Risk-Benefit Ratio in CRC With Molecular Subtyping

August 16th 2015

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

Dr. Garcia-Carbonero on Quality of Life Impact of FOLFIRI Plus Ramucirumab in mCRC

August 7th 2015

Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.

Options in Unresectable Metastatic Colorectal Cancer

July 29th 2015

Initial Treatments for Newly Diagnosed Colorectal Cancer

July 29th 2015

Communicating Test Results to Patients

July 29th 2015

Mutation Analysis in Colorectal Cancer

July 29th 2015

Biopsy for Colorectal Cancer

July 29th 2015

Discussing Genetic Testing in Colorectal Cancer

July 29th 2015

Effective Communication in Colorectal Cancer

July 29th 2015

Dr. Arber on Aspirin for Colorectal Cancer Prevention

July 27th 2015

Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.

Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal Cancer

July 23rd 2015

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC

July 16th 2015

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Global Perspective on the ASCO Annual Meeting

July 16th 2015

New Agents for Refractory Metastatic Colorectal Cancer

July 16th 2015

Immunotherapy in Colorectal Cancer

July 16th 2015

Maintenance Therapy in Colorectal Cancer

July 16th 2015

EGFR Inhibition in RAS Wild-Type Unresectable mCRC

July 16th 2015